

Raffaella Giavazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/119565/publications.pdf>

Version: 2024-02-01

174
papers

9,251
citations

34016

52
h-index

46693

89
g-index

180
all docs

180
docs citations

180
times ranked

10962
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial Cells. <i>American Journal of Pathology</i> , 2002, 160, 673-680. | 1.9 | 502 |
| 2 | Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.. <i>Journal of Cell Biology</i> , 1990, 111, 765-772. | 2.3 | 392 |
| 3 | Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. <i>Cancer Research</i> , 1986, 46, 4109-15. | 0.4 | 390 |
| 4 | Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>American Journal of Pathology</i> , 2000, 157, 1703-1711. | 1.9 | 322 |
| 5 | Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. <i>Cancer Research</i> , 2003, 63, 5224-9. | 0.4 | 241 |
| 6 | Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. <i>International Journal of Cancer</i> , 1994, 58, 460-464. | 2.3 | 212 |
| 7 | Matrix metalloproteinase inhibition: A review of anti-tumour activity. <i>Annals of Oncology</i> , 1995, 6, 967-974. | 0.6 | 203 |
| 8 | Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions.. <i>Journal of Clinical Investigation</i> , 1993, 92, 3038-3044. | 3.9 | 197 |
| 9 | Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH. <i>Neoplasia</i> , 2006, 8, 96-103. | 2.3 | 168 |
| 10 | Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis. <i>American Journal of Pathology</i> , 2003, 162, 1913-1926. | 1.9 | 167 |
| 11 | Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. <i>Cancer Research</i> , 1990, 50, 4771-5. | 0.4 | 159 |
| 12 | The heparin binding 25 kDa fragment of thrombospondinâ€1 promotes angiogenesis and modulates gelatinase and TIMPâ€2 production in endothelial cells. <i>FASEB Journal</i> , 2000, 14, 1674-1676. | 0.2 | 146 |
| 13 | Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin. <i>Clinical Cancer Research</i> , 2004, 10, 4813-4821. | 3.2 | 144 |
| 14 | Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. <i>Leukemia</i> , 2003, 17, 52-59. | 3.3 | 142 |
| 15 | In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. <i>Nature Methods</i> , 2005, 2, 291-298. | 9.0 | 141 |
| 16 | Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. <i>Human Gene Therapy</i> , 1995, 6, 813-819. | 1.4 | 137 |
| 17 | An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. <i>Science</i> , 1991, 251, 1363-1366. | 6.0 | 132 |
| 18 | Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells.. <i>Journal of Clinical Investigation</i> , 1988, 82, 1466-1470. | 3.9 | 132 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models. <i>Cancer Research</i> , 2011, 71, 1396-1405. | 0.4 | 131 |
| 20 | Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. <i>Cancer Research</i> , 2014, 74, 6980-6990. | 0.4 | 110 |
| 21 | A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.. <i>Journal of Clinical Investigation</i> , 1993, 92, 2160-2167. | 3.9 | 107 |
| 22 | Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. <i>British Journal of Cancer</i> , 1980, 42, 462-472. | 2.9 | 102 |
| 23 | Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. <i>International Journal of Cancer</i> , 1989, 44, 707-713. | 2.3 | 99 |
| 24 | Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. <i>Cancer Research</i> , 2003, 63, 1534-7. | 0.4 | 94 |
| 25 | Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. <i>Blood</i> , 2003, 102, 4399-4406. | 0.6 | 93 |
| 26 | High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. <i>Annals of Oncology</i> , 1999, 10, 1233-1240. | 0.6 | 90 |
| 27 | Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. <i>European Journal of Cancer</i> , 2006, 42, 2821-2832. | 1.3 | 90 |
| 28 | Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. <i>Clinical Cancer Research</i> , 1998, 4, 1977-83. | 3.2 | 88 |
| 29 | Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectinâ€Positive Metastatic Human Melanoma Xenografts. <i>Cancer Research</i> , 2012, 72, 1814-1824. | 0.4 | 86 |
| 30 | Antiangiogenic activity of aplidine, a new agent of marine origin. <i>British Journal of Cancer</i> , 2004, 90, 2418-2424. | 2.9 | 82 |
| 31 | Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. <i>Cancer Research</i> , 1992, 52, 2628-30. | 0.4 | 81 |
| 32 | Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. <i>Journal of Biological Chemistry</i> , 2010, 285, 8733-8742. | 1.6 | 70 |
| 33 | Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. <i>Scientific Reports</i> , 2016, 6, 39284. | 1.6 | 68 |
| 34 | Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 700-709. | 1.2 | 67 |
| 35 | The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. <i>EMBO Molecular Medicine</i> , 2011, 3, 480-494. | 3.3 | 67 |
| 36 | Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. <i>Molecular Cancer Research</i> , 2008, 6, 525-534. | 1.5 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Vascular Disrupting Activity of Tubulin-Binding 1,5-Diaryl-1 <i>H</i> -imidazoles. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7906-7910. | 2.9 | 65 |
| 38 | Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents. <i>Frontiers in Oncology</i> , 2013, 3, 259. | 1.3 | 65 |
| 39 | Retroviral Vector-Mediated Gene Transfer into Human Primary Myogenic Cells Leads to Expression in Muscle Fibers <i>In Vivo</i> . <i>Human Gene Therapy</i> , 1993, 4, 713-723. | 1.4 | 61 |
| 40 | An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. <i>Oncogene</i> , 2004, 23, 8859-8867. | 2.6 | 61 |
| 41 | Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. <i>International Journal of Cancer</i> , 1980, 25, 617-620. | 2.3 | 60 |
| 42 | Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. <i>International Journal of Cancer</i> , 1989, 44, 494-500. | 2.3 | 58 |
| 43 | The Immunocytokine F8-IL2 Improves the Therapeutic Performance of Sunitinib in a Mouse Model of Renal Cell Carcinoma. <i>Journal of Urology</i> , 2010, 184, 2540-2548. | 0.2 | 58 |
| 44 | Growth potential of human colorectal carcinomas in nude mice: association with the preoperative serum concentration of carcinoembryonic antigen in patients. <i>Cancer Research</i> , 1988, 48, 1689-92. | 0.4 | 58 |
| 45 | Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. <i>Cancer Research</i> , 1993, 53, 5051-4. | 0.4 | 58 |
| 46 | Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. <i>BMC Genomics</i> , 2008, 9, 201. | 1.2 | 56 |
| 47 | Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. <i>American Journal of Pathology</i> , 2014, 184, 1050-1061. | 1.9 | 56 |
| 48 | Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 125-135. | 1.9 | 56 |
| 49 | Soluble stroma-related biomarkers of pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, . | 3.3 | 56 |
| 50 | Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. <i>European Journal of Cancer</i> , 1981, 17, 71-76. | 1.0 | 55 |
| 51 | The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. <i>Clinical Cancer Research</i> , 2006, 12, 1839-1849. | 3.2 | 54 |
| 52 | Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging. <i>PLoS ONE</i> , 2013, 8, e72532. | 1.1 | 54 |
| 53 | Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. <i>British Journal of Haematology</i> , 2005, 128, 310-317. | 1.2 | 52 |
| 54 | p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. <i>Oncogene</i> , 2001, 20, 7293-7300. | 2.6 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP α 1 and TIMP α 2 and tumor thrombospondin α 1. <i>International Journal of Cancer</i> , 2015, 136, 721-729. | 2.3 | 50 |
| 56 | Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. <i>Clinical Cancer Research</i> , 2002, 8, 1182-8. | 3.2 | 50 |
| 57 | Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. <i>British Journal of Cancer</i> , 2007, 97, 888-894. | 2.9 | 49 |
| 58 | Comparative Analysis of the Membrane Proteome of Closely Related Metastatic and Nonmetastatic Tumor Cells. <i>Cancer Research</i> , 2009, 69, 5406-5414. | 0.4 | 48 |
| 59 | Synthesis and evaluation of stereopure α -trifluoromethyl-malic hydroxamates as inhibitors of matrix metalloproteinases. <i>Tetrahedron Letters</i> , 2004, 45, 1611-1615. | 0.7 | 47 |
| 60 | Matrigel promotes retinoblastoma cell growth in vitro and in vivo. <i>International Journal of Cancer</i> , 1992, 52, 234-240. | 2.3 | 46 |
| 61 | Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 111-21. | 1.9 | 46 |
| 62 | Thrombospondin α 1 is part of a Slug α -independent motility and metastatic program in cutaneous melanoma, in association with VEGFR α 1 and FGF α 2. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 73-81. | 1.5 | 45 |
| 63 | The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. <i>Clinical Cancer Research</i> , 2003, 9, 3476-85. | 3.2 | 45 |
| 64 | Enhancement of Metastatic Potential of Murine and Human Melanoma Cells by Laminin Receptor Peptide G: Attachment of Cancer Cells to Subendothelial Matrix as a Pathway for Hematogenous Metastasis. <i>Journal of the National Cancer Institute</i> , 1993, 85, 235-240. | 3.0 | 44 |
| 65 | Mesothelial cells induce the motility of human ovarian carcinoma cells. , 1999, 80, 303-307. | | 44 |
| 66 | Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81. | | 44 |
| 67 | Interleukin-1 β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1 α . <i>European Journal of Cancer</i> , 2010, 46, 3400-3408. | 1.3 | 44 |
| 68 | A complex of α 6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. <i>EMBO Molecular Medicine</i> , 2012, 4, 1156-1175. | 3.3 | 44 |
| 69 | Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. <i>Experimental Cell Research</i> , 2000, 258, 384-394. | 1.2 | 43 |
| 70 | Organ distribution of experimental metastases of a human colorectal carcinoma injected in nude mice. <i>Clinical and Experimental Metastasis</i> , 1989, 7, 55-68. | 1.7 | 42 |
| 71 | Preclinical development of metalloprotease inhibitors in cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 53-60. | 2.0 | 41 |
| 72 | Distribution of mono-, di, and tri-O-acetylated sialic acids in normal and neoplastic colon. <i>Cancer Research</i> , 1988, 48, 483-9. | 0.4 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | A Proteomic Approach for the Identification of Vascular Markers of Liver Metastasis. <i>Cancer Research</i> , 2010, 70, 309-318. | 0.4 | 40 |
| 74 | Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1167-1178. | 2.4 | 40 |
| 75 | Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1529-1535. | 0.9 | 39 |
| 76 | The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 131-140. | 1.9 | 39 |
| 77 | Correlation between the in vitro interaction of tumor cells with an organ environment and metastatic behavior in vivo. <i>Invasion & Metastasis</i> , 1987, 7, 16-29. | 0.5 | 39 |
| 78 | Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. <i>Oncotarget</i> , 2015, 6, 3043-3054. | 0.8 | 38 |
| 79 | A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. <i>ELife</i> , 2019, 8, . | 2.8 | 38 |
| 80 | Comparative study on the metastatic behavior of human tumors in nude, beige/nude/xid and severe combined immunodeficient mice. <i>Invasion & Metastasis</i> , 1993, 13, 82-91. | 0.5 | 38 |
| 81 | Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 879-887. | 1.1 | 37 |
| 82 | Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variants. <i>Experimental Cell Research</i> , 1990, 190, 69-75. | 1.2 | 36 |
| 83 | Targeting angiogenesis with compounds from the extracellular matrix. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1674-1685. | 1.2 | 36 |
| 84 | Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. <i>American Journal of Pathology</i> , 1998, 152, 1607-16. | 1.9 | 36 |
| 85 | Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 655-662. | 1.7 | 35 |
| 86 | Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. <i>Oncogene</i> , 2016, 35, 6212-6222. | 2.6 | 35 |
| 87 | Correlation of Tumor Growth Inhibitory Activity of Macrophages Exposed to Adriamycin and Adriamycin Sensitivity of the Target Tumor Cells. <i>Journal of the National Cancer Institute</i> , 1984, 73, 447-455. | 3.0 | 34 |
| 88 | IL-1 β gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. , 1996, 67, 856-863. | | 34 |
| 89 | Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. <i>British Journal of Cancer</i> , 1988, 57, 277-280. | 2.9 | 33 |
| 90 | Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. <i>Chinese Journal of Cancer</i> , 2016, 35, 61. | 4.9 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line. <i>Cancer Research</i> , 1983, 43, 2216-22. | 0.4 | 32 |
| 92 | The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma. <i>Neoplasia</i> , 2009, 11, 1155-IN7. | 2.3 | 31 |
| 93 | The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions. <i>Oncogene</i> , 2021, 40, 1721-1736. | 2.6 | 31 |
| 94 | Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues. <i>Cancer Research</i> , 1988, 48, 2353-60. | 0.4 | 31 |
| 95 | A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. <i>Histochemistry and Cell Biology</i> , 2010, 133, 467-475. | 0.8 | 30 |
| 96 | Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. <i>Cancer Research</i> , 1995, 55, 4729-38. | 0.4 | 30 |
| 97 | Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. <i>British Journal of Cancer</i> , 2012, 107, 360-369. | 2.9 | 29 |
| 98 | Inhibition of matrix metalloproteinases by overexpression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. <i>International Journal of Cancer</i> , 2001, 91, 241-247. | 2.3 | 29 |
| 99 | Syngeneic Murine Metastasis Models: B16 Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1070, 131-140. | 0.4 | 29 |
| 100 | Expression of cell surface P-glycoprotein by an Adriamycin-resistant murine fibrosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1984, 13, 145-7. | 1.1 | 28 |
| 101 | Outbreaks of hyperkeratotic dermatitis of athymic nude mice in northern Italy. <i>Laboratory Animals</i> , 1997, 31, 206-211. | 0.5 | 28 |
| 102 | Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. <i>Thrombosis and Haemostasis</i> , 2004, 91, 403-411. | 1.8 | 28 |
| 103 | Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. <i>Neoplasia</i> , 2012, 14, 846-IN16. | 2.3 | 28 |
| 104 | Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. <i>Carcinogenesis</i> , 2019, 40, 303-312. | 1.3 | 28 |
| 105 | Growth and metastatic behavior of human tumor cells implanted into nude and beige nude mice. <i>Clinical and Experimental Metastasis</i> , 1987, 5, 135-146. | 1.7 | 27 |
| 106 | Thrombospondin-1/HIV-1 Tat protein interaction: modulation of the biological activity of extracellular Tat. <i>FASEB Journal</i> , 2000, 14, 1917-1930. | 0.2 | 27 |
| 107 | Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 715-725. | 1.9 | 27 |
| 108 | VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. <i>Journal of Hematology and Oncology</i> , 2021, 14, 186. | 6.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Mononuclear phagocyte adherence in the presence of laminin. <i>Experimental Cell Research</i> , 1983, 146, 391-399. | 1.2 | 25 |
| 110 | Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. <i>British Journal of Dermatology</i> , 2011, 164, 1061-1070. | 1.4 | 25 |
| 111 | Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. <i>Annals of Oncology</i> , 1993, 4, 151-155. | 0.6 | 24 |
| 112 | Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. <i>Clinical Cancer Research</i> , 2005, 11, 2720-2726. | 3.2 | 23 |
| 113 | Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2237-2247. | 1.9 | 23 |
| 114 | Driving p53 Response to Bax Activation Greatly Enhances Sensitivity to Taxol by Inducing Massive Apoptosis. <i>Neoplasia</i> , 2000, 2, 202-207. | 2.3 | 22 |
| 115 | Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. <i>Angiogenesis</i> , 2017, 20, 233-241. | 3.7 | 22 |
| 116 | Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. , 1997, 70, 72-77. | | 21 |
| 117 | Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix. <i>European Journal of Cancer</i> , 2005, 41, 470-476. | 1.3 | 21 |
| 118 | A murine ovarian tumor with unique metastasizing capacity. <i>European Journal of Cancer</i> , 1981, 17, 651-653. | 1.0 | 19 |
| 119 | Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. <i>European Journal of Cancer</i> , 2009, 45, 454-460. | 1.3 | 19 |
| 120 | A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. <i>Leukemia Research</i> , 1997, 21, 1107-1114. | 0.4 | 18 |
| 121 | Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 43-53. | 1.7 | 18 |
| 122 | Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. <i>Thrombosis and Haemostasis</i> , 2011, 106, 705-711. | 1.8 | 18 |
| 123 | Anti-angiogenesis for cancer: Current status and prospects. <i>Thrombosis Research</i> , 2018, 164, S3-S6. | 0.8 | 18 |
| 124 | Laminin inhibits the adhesion of a murine tumor of macrophage origin. <i>Experimental Cell Research</i> , 1982, 140, 315-322. | 1.2 | 17 |
| 125 | Impact of VEGFâ€dependent tumour microâ€environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. <i>Journal of Pathology</i> , 2009, 219, 455-462. | 2.1 | 17 |
| 126 | Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 647-658. | 1.7 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Cytokines and Cell Adhesion Molecules in Tumor-Endothelial Cell Interaction and Metastasis. <i>Cell Adhesion and Communication</i> , 1994, 2, 219-224. | 1.7 | 15 |
| 128 | The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells. <i>Annals of Oncology</i> , 1999, 10, 589-591. | 0.6 | 15 |
| 129 | Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. <i>Endocrinology</i> , 2010, 151, 4643-4653. | 1.4 | 15 |
| 130 | Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. <i>Exs</i> , 1992, 61, 210-213. | 1.4 | 15 |
| 131 | Establishment of human acute myelogenous leukemia lines secreting interleukin-1 β in SCID mice. <i>International Journal of Cancer</i> , 1995, 61, 280-285. | 2.3 | 14 |
| 132 | Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. <i>Histochemistry and Cell Biology</i> , 2012, 137, 195-204. | 0.8 | 14 |
| 133 | Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. <i>Oncotarget</i> , 2018, 9, 24707-24717. | 0.8 | 14 |
| 134 | PGC1 β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. <i>Cancer Research</i> , 2022, 82, 1423-1434. | 0.4 | 14 |
| 135 | Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host. <i>British Journal of Cancer</i> , 1981, 43, 100-104. | 2.9 | 13 |
| 136 | Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies. <i>Current Pharmaceutical Design</i> , 2010, 16, 3921-3931. | 0.9 | 13 |
| 137 | Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. <i>Oncotarget</i> , 2015, 6, 28389-28400. | 0.8 | 13 |
| 138 | Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 481-488. | 2.7 | 12 |
| 139 | The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 555-567. | 1.9 | 11 |
| 140 | <i>In Vivo</i> Measurement of Vascular Modulation in Experimental Tumors Using a Fluorescent Contrast Agent. <i>Photochemistry and Photobiology</i> , 2008, 84, 1249-1256. | 1.3 | 10 |
| 141 | Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. <i>Journal of Surgical Research</i> , 1986, 40, 467-474. | 0.8 | 9 |
| 142 | IDN 5390: a new concept in taxane development. <i>Anti-Cancer Drugs</i> , 2003, 14, 255-258. | 0.7 | 9 |
| 143 | Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. <i>Cancers</i> , 2020, 12, 2398. | 1.7 | 9 |
| 144 | Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. <i>International Journal of Cancer</i> , 2018, 143, 2187-2199. | 2.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | CHARACTERIZATION OF NOVEL CLONAL MURINE ENDOTHELIAL CELL LINES WITH AN EXTENDED LIFE SPAN. In <i>Vitro Cellular and Developmental Biology - Animal</i> , 2000, 36, 299. | 0.7 | 7 |
| 146 | Stereochemically pure $\hat{\pm}$ -trifluoromethyl-malic hydroxamates: synthesis and evaluation as inhibitors of matrix metalloproteinases. <i>Tetrahedron</i> , 2006, 62, 10171-10181. | 1.0 | 7 |
| 147 | Inactivating STAT3: bad for tumor, good for muscle. <i>Cell Cycle</i> , 2015, 14, 939-940. | 1.3 | 7 |
| 148 | Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. <i>Analytica Chimica Acta</i> , 2018, 1042, 1-10. | 2.6 | 7 |
| 149 | Orthotopic Model of Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2016, 1464, 139-149. | 0.4 | 7 |
| 150 | Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities. <i>International Journal of Cancer</i> , 2022, 151, 240-254. | 2.3 | 7 |
| 151 | Solution state conformation and degradation of cyclopeptides containing an NGR motif. <i>Journal of Peptide Science</i> , 2005, 11, 53-59. | 0.8 | 6 |
| 152 | Drug-Homogeneity Index in Mass-Spectrometry Imaging. <i>Analytical Chemistry</i> , 2018, 90, 13257-13264. | 3.2 | 6 |
| 153 | Procoagulant activity of sarcoma sublines with different metastatic potential. <i>Blood</i> , 1981, 57, 733-735. | 0.6 | 6 |
| 154 | Syngeneic Murine Metastasis Models: B16 Melanoma. , 2001, 58, 223-229. | | 5 |
| 155 | Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. <i>Cancers</i> , 2020, 12, 2312. | 1.7 | 5 |
| 156 | Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndrome-Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. <i>Blood</i> , 1999, 94, 1747-1754. | 0.6 | 5 |
| 157 | Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000, 95, 2672-2682. | 0.6 | 5 |
| 158 | A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data. <i>GigaScience</i> , 2020, 9, . | 3.3 | 5 |
| 159 | Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 6759-6769. | 0.4 | 4 |
| 160 | Invasion and Metastasis. , 2004, , 443-461. | | 4 |
| 161 | Microtubule Targeting Agents and the Tumor Vasculature. , 2008, , 519-530. | | 4 |
| 162 | Flavone acetic acid pharmacokinetics in nude mice. <i>Anticancer Research</i> , 1990, 10, 437-9. | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Organ-specific growth of a murine lymphoma of spontaneous origin in nude mice. Clinical and Experimental Metastasis, 1991, 9, 485-497. | 1.7 | 2 |
| 164 | Adhesion of Tumor Cells Under Flow. , 1999, 96, 153-157. | | 2 |
| 165 | Vascular endothelium summary statement III: Cancer prevention and control. Vascular Pharmacology, 2007, 46, 321-323. | 1.0 | 2 |
| 166 | Combination Therapy with Chemotherapy and VDAs. , 2010, , 77-93. | | 2 |
| 167 | Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biology, 2021, 103-104, 22-36. | 1.5 | 2 |
| 168 | Anticancer Therapy with Angiogenesis Inhibitors. Tumori, 2001, 87, 14-16. | 0.6 | 1 |
| 169 | The Nude Mouse for the Study of Human Colorectal Carcinoma. Advances in Experimental Medicine and Biology, 1988, 233, 39-47. | 0.8 | 1 |
| 170 | Tumorigenic and Metastatic Properties of Human Colorectal Carcinomas Transplanted into Nude Mouse. , 1990, , 311-339. | | 1 |
| 171 | Small molecules in anti-angiogenic therapy. Current Opinion in Investigational Drugs, 2002, 3, 482-91. | 2.3 | 1 |
| 172 | Eso Conference "Biological Basis for Antiangiogenic Therapy". International Journal of Biological Markers, 1999, 14, 277-277. | 0.7 | 0 |
| 173 | Adhesion of Tumor Cells to Endothelium Under Static Conditions. , 1999, 96, 147-151. | | 0 |
| 174 | Fluorescent imaging of vascular shutdown in-vivo. , 2006, , . | | 0 |